Nicole A. Schreiber

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

11h-index1.9kcitations53works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(37), Cancer Genomics and Diagnostics(19), Cancer Cells and Metastasis(18), Radiopharmaceutical Chemistry and Applications(12), Lung Cancer Treatments and Mutations(4)

Publications53 total

Comments on and illustrations of the WFUMB CEUS liver guidelines: Rare malignant mesenchymal liver lesions
Medical Ultrasonography·2023· 3 citedOpen Access
Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Data from The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Figures 1-8, Supplementary Tables 1-6 from The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
2023Open Access
Data from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Data from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
2023Open Access
Data from The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
2023Open Access
Supplementary Figures 1-8, Supplementary Tables 1-6 from The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
2023Open Access
Abstract P011: Clonal hematopoiesis and risk of lethal prostate cancer: a prospective cohort study with long-term follow-up
Cancer Prevention Research·2023
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
European Urology Open Science·2021· 18 citedOpen Access
Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
Journal of Circulating Biomarkers·2020· 16 citedOpen Access
CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts).
Journal of Clinical Oncology·2019
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
JAMA Oncology·2018· 241 citedOpen Access
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
JAMA Oncology·2018· 237 citedOpen Access
Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples.
Journal of Clinical Oncology·2018
Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2018
Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology·2018· 8 cited
Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
Annals of Oncology·2017Open Access
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Cancer Research·2017· 134 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Howard I. Scher(42), Ryan Dittamore(35), Ryon P. Graf(28), Adam Jendrisak(27), Martin Fleisher(24), Mark Landers(23), Brigit McLaughlin(20), Jessica Louw(18), Rachel Krupa(16), Yipeng Wang(16), Dena Marrinucci(14), Jerry Lee(14), Daniel C. Danila(13), Glenn Heller(13), David Lu(12), Lyndsey Dugan(11), Stephanie Greene(9), Richard Bambury(8), Ángel Rodríguez(8), James Kelvin(7)